恒瑞醫藥(600276.SH):公司近十年累計研發投入超300億元
格隆匯12月8日丨恒瑞醫藥(600276.SH)在投資者互動平台表示,公司近十年累計研發投入超300億元,近幾年每年研發投入佔銷售收入的比重均在20%以上,位居行業前列。公司始終堅持以資金投入為基礎,以人才引領為支撐,以體系建設為保障,以“臨牀未滿足的需求”為導向,以“新、快、特”為主要宗旨,堅持“差異化”的競爭策略,持續聚焦靶點前移,加強源頭創新。通過深入瞭解疾病的特點及其人羣差異,持續關注患者端的需求變化,洞察並挖掘未被滿足的臨牀需求,體現臨牀價值。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.